Skip to content
DataLookout
Menu

IMvigor011NCT04660344

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 66 versions: 47 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Study sites: 141 to 140
  2. Notable Results posted: Sep 28, 2026 Show 4 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 34 words
    • Trial sites reduced: 148 → 141 locations
    • Secondary endpoints: details revised at 7 of 10 entries
  3. Notable Primary endpoint revised
    • Study sites: 148 to 142
    • Secondary endpoints revised (10)
    v63
  4. Minor Study sites: 161 to 148
    • Study completion date: Sep 13, 2026 to Oct 1, 2026
    • Secondary endpoints: details revised at 8 of 10 entries
    v62
  5. Minor Study sites revised (161)v61
Show 42 earlier versionsHide 42 earlier versions
  1. Notable Eligibility criteria expanded, about 4 wordsv59
  2. Notable Eligibility criteria expanded, about 35 words
    • Primary endpoint revised
    • Secondary endpoints revised (10)
    • Site details revised at 1 of 161 sites
    v58
  3. Minor Study sites: 167 to 161v57
  4. Minor Study sites revised (167)v56
  5. Notable Eligibility criteria shortened, about 19 wordsv55 Show 6 more changesShow less
    • Enrollment target: estimated 800 to confirmed 761
    • Study sites: 171 to 167
    • Primary completion date: Apr 30, 2025 to Jun 15, 2025
    • Study completion date: Jul 29, 2026 to Sep 13, 2026
    • Interventions: Atezolizumab (Drug), Placebo (Other) to Atezolizumab (Drug), Placebo (Other), Signatera (Device)
    • Study arms: 2 to 3
  6. Minor Study sites: 178 to 171v54
  7. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 211 to 178
    • Primary completion date: Mar 31, 2025 to Apr 30, 2025
    • Study completion date: Apr 1, 2031 to Jul 29, 2026
    v53
  8. Minor Study sites revised (211)v52
  9. Minor Site details revised at 1 of 211 sitesv51
  10. Minor Study sites: 210 to 211v50
  11. Minor Site details revised at 5 of 210 sitesv49
  12. Minor Study sites: 209 to 210v48
  13. Notable Enrollment target: 520 to 800v47 Show 4 more changesShow less
    • Eligibility criteria expanded, about 7 words
    • Primary endpoint revised
    • Secondary endpoints: 12 to 10
    • Site details revised at 6 of 209 sites
  14. Minor Primary completion date: Apr 3, 2025 to Mar 31, 2025
    • Study completion date: Feb 23, 2028 to Apr 1, 2031
    • Secondary endpoints revised (12)
    • Site details revised at 2 of 209 sites
    v46
  15. Minor Study sites: 207 to 209v45
  16. Minor Study sites: 206 to 207v44
  17. Minor Study sites: 202 to 206
    • Primary completion date: Mar 1, 2025 to Apr 3, 2025
    • Study completion date: Nov 22, 2027 to Feb 23, 2028
    v43
  18. Minor Study sites: 201 to 202v42
  19. Minor Study sites: 199 to 201v41
  20. Minor Site details revised at 2 of 199 sitesv40
  21. Minor Site details revised at 2 of 199 sitesv39
  22. Minor Site details revised at 6 of 199 sitesv38
  23. Minor Study sites: 200 to 199v37
  24. Notable Primary completion date: May 11, 2024 to Mar 1, 2025v36 Show 4 more changesShow less
    • Eligibility criteria expanded, about 28 words
    • Enrollment target: 495 to 520
    • Study sites: 197 to 200
    • Secondary endpoints: details revised at 10 of 12 entries
  25. Minor Study sites: 196 to 197v35
  26. Minor Study sites: 194 to 196v34
  27. Minor Study sites: 192 to 194v33
  28. Minor Study sites: 191 to 192v32
  29. Minor Study sites: 189 to 191v31
  30. Notable Eligibility criteria shortened, about 8 wordsv30
  31. Minor Study sites: 185 to 189v29
  32. Minor Site details revised at 6 of 185 sitesv28
  33. Notable Eligibility criteria expanded, about 150 words
    • Study sites: 183 to 185
    v27
  34. Minor Study sites: 177 to 183v26
  35. Minor Study sites: 173 to 177v25
  36. Minor Study sites: 171 to 173v23
  37. Minor Study sites: 168 to 171v22
  38. Minor Study sites: 156 to 168v21
  39. Minor Study sites: 151 to 156v20
  40. Minor Study sites: 144 to 151v19
  41. Minor Study sites: 133 to 144v18
  42. Minor Study sites: 118 to 133v17
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

INV-assessed Disease-free Survival (DFS)
Timeframe: From randomization to the first occurrence of a DFS event (Up to 48.2 months)

Secondary (10)

Overall Survival (OS)
Independent Review Facility (IRF)-Assessed DFS
INV-assessed Disease-specific Survival (DSS)
INV-assessed Distant Metastasis-free Survival (DMFS)
Time to Confirmed Deterioration (TTCD) in Physical Functioning, Role Functioning & Global Health Status/Quality of Life (GHS/QoL), Assessed by European Organisation for Research & Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Show 5 moreShow less
Percentage of Participants With ctDNA Clearance
Number of Participants With Adverse Events (AEs)
Maximum Serum Concentration (Cmax) of Atezolizumab
Minimum Serum Concentration (Cmin) of Atezolizumab
Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab

Arms and interventions

Arm A: AtezolizumabExperimental

Atezolizumab will be administered intravenously (IV) at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.

Arm B: PlaceboPlacebo comparator

Placebo will be administered IV on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor. Following the primary analysis, participants randomized to the comparator arm might discontinue placebo and may receive treatment outside the study at the investigator's discretion.

Arm C: Surveillance Follow-UpExperimental

Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter surveillance follow-up.

Drugs: Atezolizumab

Other: Placebo

Devices: Signatera

Sites

140 sites in 23 countries

Japan 21, Spain 13, China 12, Italy 11, United Kingdom 11, France 10, Brazil 8, Turkey (Türkiye) 8, Germany 6, Greece 5, Ukraine 5, Poland 4, Russia 4, South Korea 4, Colombia 3, Czechia 3, United States 3, Argentina 2, Belgium 2, Ireland 2, Hong Kong 1, Israel 1, Singapore 1